University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone

Simple item page
dc.contributor.authorPrice, David
dc.contributor.authorHenley, William
dc.contributor.authorCarter, Victoria
dc.contributor.authorSkinner, D
dc.contributor.authorVella, Rebecca
dc.contributor.authorPapi, A.
dc.contributor.authorFabbri, Leonardo M
dc.contributor.authorKertsjens, H
dc.contributor.authorRoche, N
dc.contributor.authorSingh, D
dc.contributor.authorVogelmeier, C
dc.contributor.authorSen, E
dc.contributor.authorCancado, J
dc.contributor.authorNudo, Elena
dc.contributor.authorBarile, Sara
dc.contributor.authorGeorges, George
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.date.accessioned2024-04-08T08:19:02Z
dc.date.available2024-04-08T08:19:02Z
dc.date.embargoedUntil2023-03-16
dc.date.issued2022-03
dc.descriptionGrant support: This study was funded by Chiesi Farmaceutici S.p.A. David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.en
dc.description.statusPeer revieweden
dc.format.extent1
dc.format.extent70613
dc.identifier288669989
dc.identifierae64096f-e9c0-4f2c-949f-e3e23086d287
dc.identifier.citationPrice, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, L M, Kertsjens, H, Roche, N, Singh, D, Vogelmeier, C, Sen, E, Cancado, J, Nudo, E, Barile, S & Georges, G 2022, 'Lower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone', Respirology, vol. 27, no. S1, TO 098, pp. 81. https://doi.org/10.1111/resp.14216en
dc.identifier.doi10.1111/resp.14216
dc.identifier.issn1323-7799
dc.identifier.urihttps://hdl.handle.net/2164/23180
dc.identifier.vol27en
dc.language.isoeng
dc.relation.ispartofRespirologyen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleLower pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasoneen
dc.typeJournal itemen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Price_etal_TSANZSRS_Lower_Pneumonia_Risk_AAM.pdf
Size:
68.96 KB
Format:
Adobe Portable Document Format
Download

Collections

All research